Apogee Therapeutics, Inc.
APGE
$38.40
$2.055.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.80M | 56.25M | 49.01M | 41.55M | 35.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 270.83M | 241.79M | 216.87M | 178.14M | 143.76M |
| Operating Income | -270.83M | -241.79M | -216.87M | -178.14M | -143.76M |
| Income Before Tax | -237.50M | -205.29M | -182.13M | -146.66M | -118.49M |
| Income Tax Expenses | 173.00K | 101.00K | 18.00K | -- | -- |
| Earnings from Continuing Operations | -237.67 | -205.39 | -182.15 | -146.66 | -118.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -237.67M | -205.39M | -182.15M | -146.66M | -118.49M |
| EBIT | -270.83M | -241.79M | -216.87M | -178.14M | -143.76M |
| EBITDA | -270.10M | -241.42M | -216.68M | -140.88M | -82.24M |
| EPS Basic | -4.12 | -3.59 | -3.28 | -2.76 | -2.40 |
| Normalized Basic EPS | -2.57 | -2.24 | -2.05 | -1.72 | -1.50 |
| EPS Diluted | -4.12 | -3.59 | -3.28 | -2.76 | -2.40 |
| Normalized Diluted EPS | -2.57 | -2.24 | -2.05 | -1.72 | -1.50 |
| Average Basic Shares Outstanding | 230.67M | 228.76M | 220.75M | 211.89M | 196.33M |
| Average Diluted Shares Outstanding | 230.67M | 228.76M | 220.75M | 211.89M | 196.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |